Australian company Noxopharm (ASX:NOX) has joined the Alliance for mRNA Medicines (AMM).
The AMM is a global organisation dedicated to advancing and advocating for mRNA and next-generation encoding RNA therapeutics and vaccines.
Noxopharm said joining the AMM means it will connect with other organisations, including CSL and BioNTech, working to progress mRNA and other RNA technologies.
Noxopharm's Sofra technology platform contains assets such as the SOF-VAC mRNA vaccine enhancer and SOF-SKN lupus medication.
According to Precedence Research, the mRNA market in 2022 was US$40 billion and is expected to reach US$137 billion by 2032.
AMM’s executive director, Clay Alspach, said: “We are delighted to welcome Noxopharm into the Alliance and believe that the team can make a real contribution to our organisation, especially in the Asia Pacific region. Noxopharm’s groundbreaking work offers an attractive addition to the wide range of new and emerging technologies represented by our members.”
Noxopharm CEO Dr Gisela Mautner added, “AMM is driving the promotion of mRNA-related technologies both in the US and around the world, and advancing policies and regulatory solutions that will allow our industry to grow rapidly and fulfil its promise. We are very pleased to join this illustrious group and look forward to playing our part to help shape our collective future.”